Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Genitourinary 2Thoracic 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peposertib × Gynecologic × Clear all
NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡